Intrathecal and Intraventricular Administration of Antibiotics in Gram-Negative Nosocomial Meningitis in a Research Hospital in Turkey

Muge AYHAN¹, Ayse KAYA KALEM², Imran HASANOGLU², Bircan KAYAASLAN², Mehmet Ozgur OZATES³, Seval IZDES⁴, Burcin HALACLI⁵, Hatice Rahmet GUNER²

¹Ankara City Hospital, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey

²Ankara Yildirim Beyazit University, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey

³Ankara City Hospital, Department of Neurosurgery, Ankara, Turkey

⁴Ankara Yildirim Beyazit University, Department of Anaesthesia and Intensive Care, Ankara, Turkey

⁵Hacettepe University, School of Medicine, Department of Internal Medicine, Division of Intensive Care, Ankara, Turkey

This study has been presented as an oral presentation at the BUHASDER Congress between 16 and 20 October 2019 at Izmir, Turkey.

Corresponding author: Muge AYHAN ✉ dr.mugeayhan@hotmail.com

ABSTRACT

AIM: To evaluate the gram-negative nosocomial meningitis cases which were treated with intrathecal (IT) / intraventricular (IVT) antibiotics.

MATERIAL and METHODS: Medical records were reviewed for IT/IVT antibiotherapy. Gram-negative nosocomial meningitis cases treated with IT/IVT antibiotherapy additional to systemic antibiotics were included. All patients' sex, age, SOFA scores, surgical history, cerebrospinal fluid (CSF) culture results, CSF cell counts, systemic and IT/IVT antibiotics, their dosages and duration, CSF culture sterility and sterility time, 28-day mortality due to meningitis, and all other causes were recorded and analyzed.

RESULTS: Thirteen patients were included between 2014 and 2018. Most common microorganism was *Acinetobacter baumannii* (*A.baumannii*) (8/13). IT/IVT antibiotics were chosen according to susceptibility. Colistin was used in eight patients, amikacin was used in four, and one patient used amikacin and colistin consecutively. Culture negativity could not be achieved in two patients. Eight patients clinically improved but five patients had no clinical response. 28-day mortality due to infection occurred in 2 of 13 patients (15%). 28-day all-cause mortality occurred in 3 of 13 patients (23%).

CONCLUSION: In our study, CSF culture negativity rate was high. IT/IVT antibiotic therapy should be considered as an effective and acceptable treatment option, especially in patients who do not respond to standard IV antibiotherapy.

KEYWORDS: Meningitis, Ventriculitis, Intrathecal, Intraventricular, Antibiotics

ABBREVIATIONS: IV: Intravenous, IT: Intrathecal, IVT: Intraventricular, SOFA: Sequential organ failure assessment, CSF: Cerebrospinal fluid, CNS: Central nervous system

■ INTRODUCTION

Blood-brain barrier protects central nervous system (CNS) against microbial entry from blood, while skull and leptomeninges protect it externally against entry of microorganisms. But in some situations, pathogens may enter CNS through a breakdown of blood-brain barrier or by direct invasion through external barriers (23). Nosocomial CNS infections can be complications of neurosurgical procedures or they can occur spontaneously. Nosocomial bacterial meningitis can be caused by internal or external drainage catheter placement, lumbar puncture, intrathecal infusion of medications, or spinal anesthesia and complicated head trauma (12). They can lead to important neurological complications and cause increased mortality. They can also result in longer hospital stay and increased costs (5,14). Reported rates of CNS infections depend on intervention type (4). Nosocomial meningitis occurs in 0.8 to 1.5% of patients who undergo cranial surgery. Post-operative meningitis represents nearly 30% of all post-neurosurgery infections. Carbapenem resistant gram-negative post-operative meningitis is associated with high mortality rates up to 60-70% (13). Clinically it can be difficult to diagnose. Normal CSF cell count, protein and/or glucose, and a negative CSF gram-stain do not exclude the presence of infection. CSF cultures are the most important tests to establish the diagnosis (7). The causative agent is frequently coagulase negative staphylococci amongst gram-positives. Amongst gram-negative rods, *A.baumannii*, aerobic gram negative enteric microorganisms (e.g *Klebsiella pneumoniae* (*K.pneumoniae*)) can be seen. A gram-negative origin is associated with severe underlying conditions and poor outcome (18). Risk factors for meningitis or ventriculitis are leakage of CSF, concomitant infection at the time of cranial surgery, prolonged or repeated surgery, prolonged ventricular drainage, surgery through the sinuses, and the severity of underlying diseases (1). These infections are complex and difficult to treat because bacteria are becoming increasingly resistant to the most commonly used antibiotics. Another challenge is that attaining effective antibiotic concentration within the CNS is difficult, because blood-brain barrier decreases antibiotic penetration from reaching the desired area. Various approaches have been tried to achieve therapeutic levels in the central nervous system. Some of these approaches are, increasing antibiotic dosage, choosing small molecular weight antibiotics, and using antibiotics which bind to plasma proteins less. Despite all these strategies, it is difficult to reach the appropriate drug concentration within the CNS without systemic toxicity (14). This has led to increased use of intrathecal (IT) or intraventricular (IVT) antibiotics to treat CNS infections effectively. Similarly, IT antibiotics have been studied in severe meningitis (with or without ventriculitis) (8,9,19,20). In a randomized controlled study, which studied the effectiveness and safety of IT antibiotherapy and performed on infants who has gram-negative meningitis, the use of IT antibiotics in addition to intravenous (IV) antibiotics resulted in a 3-fold increase in relative mortality compared to standard antibiotic regimen (18). Therefore, IT antibiotic therapy should only be used as a last option if standard IV treatment fails or is likely to fail due to in vitro susceptibility testing (15). In this study, we aimed to

evaluate cases of patients who received IT antibiotherapy for gram-negative nosocomial meningitis in our hospital.

■ MATERIAL and METHODS

This study was performed in Ankara Atatürk Research and Training Hospital. All patients, who were consulted to infectious diseases and clinical microbiology department, were retrospectively screened through consultation forms for nosocomial meningitis with previous IT or IVT antibiotic therapy. Thirteen cases were found between 2014 and 2018. All patients' sex, age, SOFA scores, surgical history, CSF culture results, CSF cell counts, systemic and IT/IVT antibiotics, their dosages and duration, CSF culture sterility, CSF culture sterility time, 28-day mortality due to meningitis, and all other causes were recorded in a follow-up questionnaire. All patients were treated empirically with IV antibiotics. Antibiotic treatment was later adjusted according to culture results. The CSF analysis was repeated once a week until CSF culture was negative. If the control CSF culture was positive, IT or IVT antibiotics were added. After 48-72 hours control of CSF culture, the process was repeated in 2-day intervals until sterility of CSF culture was achieved.

This study was approved by Ethics Committee of Clinical Research of Yıldırım Beyazıt University (Approval Date: 29 May 2019, Approval Number: 73). The study was carried out according to principles of Helsinki Declaration. Informed consent was not obtained because this study was designed as a retrospective study.

Antibiotic Administration

Patients' CSF culture results and antibiotic susceptibility results were evaluated. Systemic and IT/IVT antibiotic therapy were given together. All IT/IVT antibiotics were given at 24-hour intervals. Two antimicrobial agents were used for IT/IVT treatment. Colistin was given at a dose of 10 mg/day, while amikacin was given at a dose of 30 mg/day. If patient has extraventricular drainage catheter (EVD), antibiotic was given through the catheter. Otherwise, it was given with daily lumbar punctures.

■ RESULTS

Between 2014 and 2018, 13 patients were given IT/IVT antibiotherapy. Eleven patients were male (84%). The median age was 54 (16-65). Seven patients were followed in neurosurgical intensive care unit (ICU), four were followed in anesthesiology and reanimation ICU, and two were followed in medical ICU. All patients were intensive care patients and mean SOFA score was 5.7. Eleven patients had had cranial surgery (84%). Six of 13 patients had EVD. Eight patients had *A.baumannii* growth on CSF, and 5 had *K.pneumoniae* (Table I). Table II shows the antimicrobial resistance of causative microorganisms. All patients had developed clinical and laboratory signs of central nervous system infection. Systemic IV antibiotics were administered in all patients after CSF culture results were obtained. Majority of patients (12/13) was given combined antibiotic therapy with different combinations. The most common IV antibiotics given to patients were

Table 1: Clinical and Demographic Features of Included Patients

	Sex/ Age	Neurologic Disease	SOFA Score	Cranial surgery	EVD	CSF culture	Systemic antibiotics	IT/IVT antibiotic/ Dosage/Duration	Time to CSF culture sterility	Clinical response	28-day mortality (all cause)	28-day mortality (due to meningitis)
1	M/20	Yes	5	Yes	Yes	<i>A.baumannii</i>	C/S+COL+LNZ	COL/10 mg per day/ 15 days	10 days	Yes	No	No
2	F/16	No	4	Yes	No	<i>A.baumannii</i>	MEM+FOS+LNZ	AK/30 mg per day/ 20 days	4 days	Yes	No	No
3	M/18	No	1	Yes	Yes	<i>A.baumannii</i>	MEM+COL	COL/10 mg per day/ 24 days	14 days	No	No	No
4	M/65	No	6	Yes	No	<i>A.baumannii</i>	MEM+COL+TGC	COL/10 mg per day/ 14 days	10 days	Yes	No	No
5	M/54	No	5	Yes	Yes	<i>A.baumannii</i>	MEM+VA	COL/10 mg per day/ 18 days	No	No	Yes	No
6	M/48	No	6	No	No	<i>A.baumannii</i>	COL+TGC	COL/10 mg per day/ 25 days	22 days	Yes	No	No
7	M/55	No	6	No	Yes	<i>A.baumannii</i>	MEM+COL+TGC	COL/10 mg per day/ 15 days	7 days	No	No	No
8	M/56	Yes	6	Yes	No	<i>A.baumannii</i>	MEM	COL/10mg per day/ 5 days	4 days	Yes	No	No
9	F/63	No	7	Yes	No	<i>K.pneumoniae</i>	AK+MEM	AK/30mg per day/ 13 ays	No	No	Yes	Yes
10	M/65	No	6	Yes	Yes	<i>K.pneumoniae</i>	MEM+COL+TGC	AK/30 mg per day/ 21 days	12 days	Yes	No	No
11	M/39	No	9	Yes	No	<i>K.pneumoniae</i>	MEM+COL	COL/10 mg per day/ 21 days	23 days	Yes	No	No
12	M/55	No	13	Yes	Yes	<i>K.pneumoniae</i>	MEM+TGC	AK/30 mg per day/ 18 days	10 days	No	Yes	Yes
13	M/59	No	4	Yes	No	<i>K.pneumoniae</i>	MEM+AK	AK/30 mg per day/ 22 days COL/10 mg per day/ 25 days	5 days of colistin	Yes	No	No

M: Male, **F:** Female, **SOFA:** Sequential organ failure assessment, **AK:** Amikacin, **C/S:** Cefoperazone/sulbactam, **COL:** Colistin, **LNZ:** Linezolid, **FOS:** Fosfomycin, **TGC:** Tygecycline, **MEM:** Meropenem, **VA:** Vancomycin.

Table II: Antimicrobial Resistance of Causative Microorganisms Isolated from CSF Cultures

Antimicrobial agent	A.baumannii (n=8)	K.pneumoniae (n=5)	Total n=13 (%)
Amikacin	1	0	1 (7)
Carbapenems	6	4	10 (76)
Cephalosporins	8	4	12 (92)
Cotrimoxazole	8	5	13 (100)
Gentamycin	2	3	5 (38)
Colistin	1	2	3 (23)
Quinolones	8	5	13 (100)

meropenem (11/13) and colistin (7/13). IT/IVT antibiotics were added to therapy, if the culture positivity persisted despite IV antibiotic treatment. IT/IVT antibiotics were chosen according to susceptibility of the microorganism. Patients who had *A.baumannii* meningitis received IT/IVT colistin (7/8), except for one patient who had IT/IVT amikacin due to antibiotic susceptibility results. Patients who had *K.pneumoniae* meningitis received IT/IVT amikacin and colistin. Three of them received amikacin, one received colistin, and one received amikacin and colistin consecutively. Mean duration of IT/IVT antibiotherapy was 20.14 days. Culture negativity couldn't be achieved in two patients. Mean time to CSF culture negativity was 13 days with a range of 4 to 27 days. Eight patients clinically improved, but five had no clinical response. 28-day mortality due to infection occurred in 2 of the 13 patients (15%). 28-day all-cause mortality occurred in 3 of the 13 patients (23%).

■ DISCUSSION

Nosocomial CNS infection is a life-threatening condition. These types of infections can occur after neurosurgery, lumbar puncture, spinal anesthesia, severe head trauma or after ventricular drainage catheter insertion (3). The most common pathogens are *Staphylococci*, however, gram-negative bacteria are responsible for 15% of CNS infections. Gram-negative bacteria have increased as nosocomial meningitis occurs and it should be considered in the choice of empirical antibiotherapy. The frequency of neurosurgical procedures is increasing and the wide use of broad spectrum antibiotics may have changed the species distribution and antibiotic resistance profiles (12,21). *A.baumannii* is the most common gram-negative microorganism in the post-neurosurgery setting, followed by *K.pneumoniae* (10). The attributable mortality of these infections is high with a range of 15-70% without appropriate treatment. The emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) strains have made treatment of these types of infections very difficult (21). In patients who have another CNS disease (trauma, tumor, hemorrhage, neurosurgery) which cause loss of blood brain barrier integrity, CNS drug penetration may have clinical importance (18). When intravenous antibiotic treatment fails, IT or IVT antibiotic administration is needed.

Therefore, IT or IVT administration of antibiotics has become an increasingly common method for the treatment of MDR or XDR-microorganism-associated CNS infections (4). Current IDSA practical guidelines for healthcare-associated ventriculitis and meningitis suggest that IVT or IT administration of antimicrobial therapy can be considered as an option for patients with healthcare-associated ventriculitis and meningitis in which the response to the standard systemic antimicrobials is poor. Several reports showed that use of some antimicrobials (eg. Polymyxin B, colistimethate sodium, gentamicin and vancomycin) is not associated with severe or irreversible toxicity (22,24). There are comparative prospective studies that reported that intraventricularly administered antimicrobials show better pharmacodynamic features and similar efficacy and safety when compared to IV antimicrobials (17).

We performed a retrospective observational study aiming to assess the efficacy and treatment results of IT/IVT antibiotic administration in our patient population. We retrospectively searched consultation forms for patients who were administered IT or IVT antimicrobial therapy. Thirteen cases were found. Identified pathogens were *A.baumannii* (61.5%) and *K.pneumoniae* (38.4%). Clinical response was observed in nine of patients (69%). Several case reports and case series were reported (Table III). In previous studies, the cure rate for patients who received a combination of IV/IT antimicrobials ranged from 71.4% to 100%. We had a lower response rate. This difference might be because our strains were more resistant to antibiotics and because of the severity of the underlying conditions. In four of the five patients without a clinical response, there was EVD. Three of these patients had XDR *A.baumannii* and two had carbapenem-resistant *K.pneumoniae*. Therefore, clinical response could not be obtained with IT/IVT antibiotherapy.

Wang et al. evaluated intraventricular antimicrobial therapy in postneurosurgical gram-negative meningitis. Fourteen patients were treated using a sequential combination of IV/IT antibiotherapy (25). Gentamicin, amikacin, and colistin were used intrathecally. Average duration of IT therapy was 13.3 days and mean time to CSF sterility was 6.6 ± 4.6 days. In our study, average duration of therapy was 20.14 days and mean time to CSF sterility was 13 days. No adverse effects

Table III: Previous Studies of Gram-Negative Meningitis in Adults Treated with Intrathecal or Intraventricular Antibiotics

Author/Year/ Reference	Number of cases	Pathogen microorganism	Given IT/IVT antibiotics/ Dosage	Systemic antibiotics	Outcome of Infection
Vasen et al., 2000 (24)	1	<i>A.baumannii</i>	Colistin 10 mg/day	No	Cure
Rodriguez Guardado et al., 2008 (19)	8	<i>A.baumannii</i> spp.	Colistin 10 mg q12h	Colistin	Cure
Cascio et al., 2010 (2)	1	<i>A.baumannii</i>	Colistin 10 mg/day	No	Cure
Karaiskos et al., 2013 (10)	6	<i>A.baumannii</i>	Colistin 1x40 mg loading dose/day 1x20 mg maintenance dose/day	Colistin	
Wang et al., 2014 (25)	14	<i>A.baumannii</i> (7) <i>Pseudomonas</i> spp. (3) <i>E.coli</i> (2) <i>K.pneumoniae</i> (1) <i>Serratia marcescens</i> (1)	Gentamycin (4) 4-10 mg/day Amikacin (7) 10-50 mg/day Colistin (4) 2-6.4 mg/day	Imipenem Meropenem Colistin Sulbactam Ceftriaxone Ceftazidime Cefepime Trimetoprim/ Sulphamethoxazole	11/14 Cure
Dersch et al., 2014 (8)	1	<i>A.baumannii</i>	Colistin 75.000IU q12h	Colistin	Cure
Gump and Walsh, 2015 (9)	1	<i>Paeruginosa</i>	Colistin 250.000-125.000 mU qd	Colistin	Cure
Shofty et al., 2015 (20)	23	<i>A.baumannii</i> Other gram-negative bacteria	Colistin 50.000-250.000 IU/day Amikacin 25-50 mg/day	N/A	21/23 Cure
Cercioglu et al., 2017 (7)	1	<i>A.baumannii</i>	Colistin 10 mg/day	Colistin Meropenem	Cure
Chusri et al., 2017 (6)	17	<i>A.baumannii</i>	Colistin 150.000 IU/day	Carbapenems Colistin	12/17 Cure
Khan et al., 2017 (11)	21	<i>A.baumannii</i> (14) <i>K.pneumoniae</i> (3) <i>Paeruginosa</i> (1) <i>E.cloacae</i> (1) <i>Polymicrobial</i> (2)	Amikacin 40 mg/day Polymyxin B 50.000 units/day Colistin 10 mg/day	N/A	21/21 Cure
Pan et al., 2018 (16)	23	<i>A.baumannii</i>	Polymyxin B 50.000 units/day	Meropenem Imipenem Tygecycline Cefoperazone/ sulbactam	21/23 Cure
Present study, 2019	13	<i>A.baumannii</i> <i>K.pneumoniae</i>	Amikacin 30 mg/day Colistin 10 mg/day	Meropenem Cefoperazone/ Sulbactam Colistin Tygecycline Amikacin Fosfomycin	11/13 Cure

N/A: Not applicable.

were recorded in this study during hospitalization period. The duration was longer in our study that might be due to longer period of CSF sterility. In Wang et al.'s study, no toxicity was observed in patients.

The independent risk factors for gram-negative meningitis after neurosurgery were evaluated in several studies. In a study in China, a total of 65 meningitis cases were evaluated. Diabetes, EVD, and the use of lumbar drainage were found to be independent risk factors (1). In another study, older age, emergency procedures, leak of CSF, presence of EVD, intensive care admission, repeated operations, and longer operations were independent risk factors for craniotomy meningitis (6). In our study, majority of patients (11/13, 84.6%) have had cranial surgery, all of whom were intensive care patients and six had EVD. Our findings were consistent with the previous literature.

In a case series of 40 patients with *A.baumannii* meningitis, the mortality was 39%, while 55% of them had carbapenem resistant isolates. Use of either intrathecal or intraventricular colistin in those with carbapenem resistance were associated with a cure of infection (13).

In the past, the major concern related to IT/IVT antimicrobial therapy was the possible adverse effects such as seizure, chemical meningitis or ventriculitis, or hearing loss (2,6). No toxicity and serious adverse events were reported (6,11). The first limitation of our study is the small sample size and the results were not comparable. The second with a retrospective study like our study, it is difficult to evaluate the optimal regimens, dosages, and durations for IT/IVT antibiotherapy. Further prospective randomized controlled trials are needed to evaluate the efficacy and safety of IT/IVT antibiotherapy in larger patient settings.

CONCLUSION

In conclusion, this study evaluates the clinical, microbiological outcomes of patients with *A.baumannii* and *K.pneumoniae* meningitis. In our study, CSF culture negativity rate was high. This result, with no toxicity or adverse effects, makes IT/IVT antibiotic therapy an effective and acceptable treatment option, especially in patients who do not respond to standard IV antibiotherapy. However, further large scale randomized controlled trials are needed.

REFERENCES

- Bargiacchi O, De Rosa FG: Intrathecal or intraventricular colistin: A review. *Infez Med* 24(1):3-11, 2016
- Cascio A, Conti A, Sinardi L, Iaria C, Angileri FF, Stassi G, David T, Versaci A, Iaria M, David A: Post-neurosurgical multidrug-resistant *Acinetobacter baumannii* meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. *Int J Infect Dis* 14(7):572-579, 2010
- Cercioglu D, Cesur S, Ataman-Hatipoglu C, Yildirim M, Celik H, Kinikli S, Bayar MA: Nosocomial meningitis due to multidrug-resistant *Acinetobacter baumannii* successfully treated with intrathecal colistin. *Klinik Derg* 30(3):155-157, 2017
- Ceylan B, Arslan F, Sipahi OR, Sunbul M, Ormen B, Hakyemez IN, Turunc T, Yildiz Y, Karsen H, Karagoz G, Tekin R, Hizarci B, Turhan V, Senol S, Oztoprak N, Yilmaz M, Ozdemir K, Mermer S, Kokoglu OF, Mert A: Variables determining mortality in patients with *Acinetobacter baumannii* meningitis/ventriculitis treated with intrathecal colistin. *Clinical Neurol Neurosurg* 153:43-49, 2016
- Chen C, Zhang B, Yu S, Sun F, Ruan Q, Zhang W, Shao L, Chen S: The incidence and risk factors of meningitis after major craniotomy in China: A retrospective cohort study. *PLoS One* 9(7):e101961, 2014
- Chen CH, Chang CY, Lin LJ, Chen WL, Chang YJ, Wang SH, Cheng CY, Yen HC: Risk factors associated with postcraniotomy meningitis: A retrospective study. *Medicine (Baltimore)* 95(31):e4329, 2016
- Chusri S, Sakarunchai I, Kositpantawong N, Panthuwong S, Santimaleeworagun W, Pattharachayakul S, Singkhamanan K, Doi Y: Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neuro surgical meningitis and ventriculitis due to carbapenem-resistant *acinetobacter baumannii*. *Int J Antimicrob Agents* 51(4):646-650, 2018
- Dersch R, Robinson E, Beume L, Rauer S, Niesen WD: Full remission in a patient with catheter-associated ventriculitis due to *Acinetobacter baumannii* treated with intrathecal and intravenous colistin besides coinfections with other multidrug-resistant bacteria. *Neurol Sci* 36(4):633-634, 2015
- Gump WC, Walsh JW: Intrathecal colistin for treatment of highly resistant *Pseudomonas ventriculitis*. *J Neurosurg* 102:915-917, 2015
- Karaiskos I, Galani L, Baziaka F, Katsouda E, Ioannidis I, Andreou A, Paskalis H, Giamarellou H: Successful treatment of extensively drug-resistant *Acinetobacter baumannii* ventriculitis and meningitis with intraventricular colistin after application of a loading dose: A case series. *Int J Antimicrob Agents* 41(5):480-483, 2013
- Khan SA, Waqas M, Siddiqui UT, Shamim MS, Nathani KR, Jooma R, Mehmood F: Intrathecal and intraventricular antibiotics for postoperative Gram-negative meningitis and ventriculitis. *Surg Neurol Int* 8:226, 2017
- Kim H, Kim S, Park G, Kwon E, Kim H& Jeong JY, Chang HH, Lee JM, Kim NS: The causes and treatment outcomes of 91 patients with adult nosocomial meningitis. *The Korean Journal of Internal Medicine* 27(2):171, 2012
- Moon C, Kwak YG, Kim BN, Kim ES, Lee CS: Implications of postneurosurgical meningitis caused by carbapenem-resistant *Acinetobacter baumannii*. *J Infect Chemother* 19:916-919, 2013
- Mrowczynski OD, Langan ST, Rizk EB: Intra-cerebrospinal fluid antibiotics to treat central nervous system infections: A review and update. *Clin Neurol Neurosurg* 170:140-158, 2018
- Nau R, Seele J, Djukic M, Eiffert H: Pharmacokinetics and pharmacodynamics of antibiotics in central nervous system infections. *Curr Opin Infect Dis* 31(1):57-68, 2018

16. Pan S, Huang X, Wang Y, Zhao C, Yao Z, Cui W, Zhang G: Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR *Acinetobacter baumannii*: A retrospective cohort study. *Antimicrob Resist Infect Control* 7:8, 2018
17. Pfausler B, Spiss H, Beer R, Kampl A, Engelhardt K, Schober M, Schmutzhard E: Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: A prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. *J Neurosurg* 98:1040-1044, 2003
18. Remês F, Tomáš R, Jindrák V, Vaniš V, Setlík M: Intraventricular and lumbar intrathecal administration of antibiotics in postneurosurgical patients with meningitis and/or ventriculitis in a serious clinical state. *J Neurosurg* 119(6):1596-1602, 2013
19. Rodriguez Guardado A, Blanco A, Asensi V, Pérez F, Rial JC, Pintado V, Bustillo E, Lantero M, Tenza E, Alvarez M, Maradona JA, Carton JA: Multidrug-resistant *Acinetobacter* meningitis in neurosurgical patients with intraventricular catheters: Assessment of different treatments. *J Antimicrob Chemother* 61(4):908-913, 2008
20. Shofty B, Neuberger A, Naffaa ME, Binawi T, Babitch T, Rappaport ZH, Zaaroor M, Svirgi G, Paul M: Intrathecal or intraventricular therapy for post-neurosurgical Gram-negative meningitis: Matched cohort study. *Clin Microbiol Infect* 22: 66-70, 2016
21. Tsimogianni A, Alexandropoulos P, Chantziara V, Vassi A, Micha G, Lagiou F, Chinou E, Michaloudis G, Georgiou S: Intrathecal or intraventricular administration of colistin, vancomycin and amikacin for central nervous system infections in neurosurgical patients in an intensive care unit. *Int J Antimicrob Agents* 49(3):389-390, 2017
22. Tunkel A, Hasbun R, Bhimraj A, Byers K, Kaplan S, Scheid W, van de Beek D, Bleck TP, Garton HJL, Zunt JR: 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. *Clinical Infectious Diseases* 64(6):34-65, 2017
23. Van de Beek D, Drake JM, Tunkel AR: Nosocomial bacterial meningitis. *N Engl J Med* 362(2):146-154, 2010
24. Vasen W, Desmery P, Ilutovich S, Di Martino A: Intrathecal use of colistin. *J Clin Microbiol* 38(9):3523, 2000
25. Wang JH, Lin PC, Chou CH, Ho CM, Lin KH, Tsai CT, Wang JH, Chi CY, Ho MW: Intraventricular antimicrobial therapy in postneurosurgical Gram-negative bacillary meningitis or ventriculitis: A hospital-based retrospective study. *J Microbiol Immunol Infect* 47(3):204-210, 2014